$AVR

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Contingent Grant of Nonqualified Stock Options to Wayne Paterson and David St Denis On September 12, 2026, Anteris Technol

Anteris Technologies (AVR) CFO Moen Brent filed an initial Form 3, disclosing no equity holdings, transactions, or derivative positions. The filing serves as a baseline for future insider ownership disclosures.

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On September 4, 2026, Anteris Technologies Global Corp. (the “Company”) appointed B

Anteris Technologies (ASX:AVR, NASDAQ:AVR) appointed Brent Moen as CFO, effective September 12, 2026. Moen has 25+ years of experience in finance, including roles at LifeLens, Tactile Systems, and Entellus Medical. Current CFO Matthew McDonnell will transition to head of Australia. Anteris develops medical devices for structural heart disease, including the DurAVR® Transcatheter Heart Valve.

The Australian S&P/ASX Small Ordinaries index was down 0.02% at market open. Tamboran Resources (TBN) and Daly Waters Energy started first gas sales from the Beetaloo Basin, with production expected to reach 40 terajoules per day by early 2027. Anteris Technologies (AVR) appointed Brent Moen as CFO, effective September 12, 2026.

L1 Capital sold 7,800 shares of Anteris Technologies (AVR) at $8.83 each on 2026-08-28, reducing its indirect stake to 4,803,541 shares. It retains 5,359,470 CHESS Depository Interests and 1,333,334 warrants, both held indirectly. The warrants expire in 2030 with an exercise price of AUD 11.50.

L1 Capital Pty Ltd sold 627,659 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $9.22 ($9.10–$9.30, $5.79M total) across 2 trades over 2026-08-10 to 2026-08-11.

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe